

Research Activities Newsletter

October 2022

In the News: Congratulations to the following awardees!!



Jessica Braymiller, Clinical Assistant Professor of Community Health and Health Behavior received an Intergovernmental Personnel Act (IPA) agreement from VA WNY Healthcare System for two projects. They are entitled: 1) *Assessing the Feasibility of Chronic Pain Prevention Strategies in Primary Care*; and 2) *Expanding Access to Behavioral Treatment for Chronic Pain: Implementing Brief Cognitive Behavior Therapy for Chronic Pain (Brief CBT-CP) in Primary Care Mental Health Integration (PCMHI)*. The first project aims to identify the VA's pain prevention priorities, assess the feasibility of implementing early pain prevention strategies in primary care, and assess the perceived impact of such prevention strategies on overall Veteran Health. The second project aims to develop a multipronged program of educational materials and technical assistance to support primary care providers with the implementation of brief CBT therapy for chronic pain.



Erin Brunelle, Occupational Therapist with CAT, received a continuation award from the Westchester Institute for Human Development entitled, *Enabling and Assistive Technology to Promote Non-Certified Housing Options for Individuals with Intellectual and/or Developmental Disabilities (IDD)*. This study will involve significant collaborations across the Oregon, Clemson, and Buffalo research teams to integrate, assess, and leverage interface concepts developed during the first NHTSA-sponsored project on ADS-DVs for vulnerable and disabled road users.



Sarah Heavey, Clinical Assistant Professor of Community Health and Health Behavior, received an Intergovernmental Personnel Act (IPA) agreement from VA WNY Healthcare System for the project entitled, *Exploring Connections between Chronic Pain, Opioid Use, and Medications for Opioid Use Disorder*. The project will design retrospective and mixed/methods studies and perform evaluations of services related to substance use disorders, chronic pain, and related concerns among Veterans.



Jeffrey Miecznikowski, Associate Professor of Biostatistics and **Christopher Stavisky**, Clinical Assistant Professor of Rehabilitation Science, are Co-Investigators on a new award from US Army Medical Research Acquisition Activity (PI: John Leddy, Orthopaedics) for the project entitled, *Exercise Reset for Concussion – Modifying the Buffalo Concussion Protocol for Application in a Military Environment*. The study will compare the current standard of care with a novel personalized medicine approach to concussion treatment. The results will produce a practical, safe treatment program that promotes recovery during the post-acute phase and that can be applied in resource-limited environments.



Gregory Wilding, Professor and Chair of Biostatistics, received an Intergovernmental Personnel Act (IPA) agreement from VA WNY Healthcare System for the project entitled, *Brief Cognitive Behavioral Therapy for Chronic Pain to Improve Functional Outcomes among Primary Care Veterans*. This study will test the effectiveness of a Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP) intervention for veterans assigned to one of two conditions in a randomized clinical trial. Analyses will focus on pain-related outcomes through the 6-month follow-up as well as examine potential mediators and moderators of outcomes. This study supports national clinical goals by examining the efficacy of a safe, accessible, non-pharmacological treatment for chronic pain early in the trajectory of care.

In This Issue

| | |
|---|----------|
| In the News: Congratulations to the Following Awardees | 1 |
| Grant Clinic | 2 |
| NIH Funding Opportunities | |
| Request for Applications (RFA) | 4 |
| Program Announcements Reviews in an Institute (PAR) | 9 |
| Individual Actions for Sustainability | 9 |

Grant Clinic

 **Effective for all NIH grant applications beginning January 25, 2023** 

Please be aware of **NIH’s New Data Management and Sharing Policy** that will be effective as of 1/25/23. NIH held informational webinars on the upcoming changes. If you were unable to attend the webinars live, recordings are located at: <https://sharing.nih.gov/about/learning>

Guidance on the new requirements can be found at: [NIH data-management-and-sharing-policy](#)

NOT-OD-22-195 – New NIH “Forms-H” Grant Application Forms and Instructions coming for Due Dates on or after January 25, 2023

NIH will be releasing new Forms-H to coincide with the new policy. Major changes include:

PHS 398 Modular Budget

“Data Management and Sharing Costs” and a brief Data Management and Sharing Justification must be provided as part of the Additional Narrative Justification

PHS 398 Research Plan

- New attachment, “Other Plan(s)”, in the Research Plan Section

GENERAL NOTICE

NOT-CA-23-009

Pre-Application Webinar for NCI’s FOAs on Advancing Adolescent Tobacco Cessation Intervention research (RFA-CA-22-042, RFA-CA-22-43)

The National Cancer Institute (NCI) will hold a pre-application webinar on **November 8, 2022, from 1:00 PM to 2:00 PM Eastern Time**, for the Funding Opportunity Announcements (FOAs), [RFA-CA-22-042](#), “Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional)” and [RFA-CA-22-043](#), “Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required).” NCI and NIDA staff will provide an overview of the FOAs, including goals and objectives, application instructions, and review criteria, and will be available to answer questions.

NOT-OD-23-010

The NIH Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Identifying Risks and Interventions to Optimize Postpartum Health

The NIH is hosting the virtual Pathways to Prevention Workshop: Identifying Risks and Interventions to Optimize Postpartum Health to assess the scientific evidence on predicting and preventing poor postpartum health outcomes and identify research gaps. The workshop is online, free and open to the public. Registration is required. Please select all days you are interested in attending in order to receive the unique

meeting link for each day. A recording of the workshop will be available approximately one month after the event. To register to attend and to receive the latest information about the workshop, visit prevention.nih.gov/P2P-PostpartumHealth. The workshop will be held November 29–December 1, 2022.

[NOT-OD-23-004](#)

Annual Reports to the Office of Laboratory Animal Welfare

This Notice is to remind awardee institutions that Annual Reports for the reporting period October 1, 2021, through September 30, 2022, are due to the NIH Office of Laboratory Animal Welfare (OLAW). **Due by** December 1, 2022.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-HD-22-043](#) – **Implementation Science to Advance Maternal Health and Maternal Health Equity for the IMPROVE initiative**

The purpose of this NOSI is to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality (MMM). This NOSI will support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve preconception, pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity. This Notice applies to due dates on or after February 6, 2023, and subsequent receipt dates through May 7, 2025.

[NOT-AG-22-030](#) – **Small Research Grants for Innovations in Health Longevity Research**

This NOSI invites applications for small research grants that align with the goals of the National Academy of Medicine's [Healthy Longevity Grand Challenge](#), as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long health span and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This Notice applies to due dates on or after February 16, 2023, and subsequent receipt dates through May 7, 2023.

[NOT-OD-22-208](#) – **Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp clinical Trial Optional)**

The Office of Research on Women's Health ([ORWH](#)) announces the availability of administrative supplements to support research highlighting health inequities among women in the US who are understudied, underrepresented and under reported (U3) in biomedical research. This NOSI encourages rigorous experimental designs, as well as the implementation of collaborative interdisciplinary research on the common causes and pathways of ill health and disease, differential risk, morbidity, and mortality, across socioecological domains and levels of influence. **Applications must be received by:** January 31, 2023

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-AI-22-072](#)

Opportunities for HIV Cure Interventions at the Time of ART Initiation

This NOSI serves to identify new opportunities for cure strategies during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART, with the ultimate goal of achieving a sustained ART-free HIV remission. Under this NOSI, clinical trials are not allowed, but the use of samples from clinical trials supported by other funding mechanisms is encouraged. For funding consideration, applicants must include "**NOT-AI-22-072**" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. This Notice applies to due dates on or after **January 7, 2023** and subsequent receipt dates through **September 7, 2025**.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

DECEMBER 2022 DUE DATES

[RFA-HS-22-010](#) (T32)

AHRQ National Research Service Award (NRSA) Institutional Research Training Grant

The objective of the NRSA T32 program is to develop and/or enhance research training opportunities for individuals interested in careers in health services, behavioral, and clinical research that are relevant to the AHRQ mission. The training program is designed to provide didactic and/or experiential training for predoctoral and postdoctoral trainees interested in: (1) improving clinical practice or the health care system's ability to provide access to and delivery of high quality, high-value health care; and/or (2) providing policymakers with the ability to assess the impact of system changes on outcomes, quality, access to, cost, and use of health care services. AHRQ strongly encourages the submission of applications in response to this NOFO from a diverse group of applicant institutions and the training of a diverse cadre of trainees. **Application Due Date:** December 1, 2022

[RFA-HD-23-035](#) (U54 Clinical Trial Optional)

Maternal Health Research Centers of Excellence

This FOA runs in parallel with companion FOAs that seek applications for an Implementation Science Hub/Resource Center ([RFA-HD-23-037](#)) and a Data Innovation and Coordinating Hub/Resource Center ([RFA-HD-23-036](#)). The goal of this initiative is for trans-disciplinary research teams to conduct multi-layered novel research projects that will have the potential to drastically reduce pregnancy-related and pregnancy-associated maternal deaths and decrease SMM. **Application Due Date:** December 5, 2022

[RFA-HD-23-036](#) (U24 Clinical Trial Not Allowed)

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center

This FOA seeks applications for the Data Innovation and Coordinating Hub/Resource Center for the Maternal Health Research Centers of Excellence initiative. This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence ([RFA-HD-23-035](#)) and an Implementation Science Hub/Resource Center ([RFA-HD-23-037](#)). Investigators with broad expertise and experience in providing an environment of excellence in clinical and public health informatics and in maximizing data comparability with projects proposed in the Research Centers to facilitate harmonization with existing large-scale research efforts should consider applying. **Application Due Date:** December 5, 2022

[RFA-HD-23-037](#) (U24 Clinical Trial Optional)

Maternal Health Research Centers of Excellence Implementation Science Hub/Resource Center

This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence ([RFA-HD-23-035](#)) and a Data Innovation and Coordinating Hub/Resource Center ([RFA-HD-23-036](#)). This FOA seeks applications from investigators with demonstrated expertise in maternal health related implementation science, including but not limited to implementation science conceptual frameworks and hybrid-effectiveness implementation design, expertise in disseminating information to diverse audiences/interested parties, serving as an implementation science consultant, integrating data elements, including needs assessments, leading process evaluations, and aiding in the design of implementation-focused sub-studies. **Application Due Date:** December 5, 2022

[RFA-OH-23-001](#) (R21)

Exploratory/Developmental Grants Related to the World Trade Center Health Program

NIOSH supports exploratory and developmental research projects that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 Health and Compensation Act of 2010 ([Public Law 111-347](#), as amended by Public Laws [114-113](#) and [116-59](#)). Enrolled WTC responders and certified-eligible WTC survivors will be included in the research project. Projects should support and facilitate the feasibility, development, and evaluation of methods, practices, interventions, and programs related to Lifestyle Medicine within the following clinical research areas: treatment research, program evaluation, screening research and health equity. **Application Due Date:** December 12, 2022

FEBRUARY 2023 DUE DATES

[RFA-DA-23-045](#) (UG1 – Clinical Trial Not Allowed)

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats

The goal of this FOA is to seek research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts. This FOA is part of the NIH's Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at <https://heal.nih.gov/>. **Application Due Date:** February 3, 2023

[RFA-DA-23-046](#) (RM1 – Clinical Trial Optional)

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On

NIDA seeks applications for multi-project RM1 Opioid Use Disorder Quality Measurement and Management Research Centers (OUD-QM²RCs). OUD-QM²RCs will involve researchers and a partner with a deployed or in-development quality measurement strategy for opioid use disorder treatment that rigorous, scientific research could substantially advance. The ultimate goal is the creation of feasible, efficient quality measurement systems that provide meaningful information to help patients, families, and payors fairly compare and select providers and to help clinicians and providers improve patient outcomes.

Application Due Date: February 3, 2023

[RFA-DA-23-051](#) (R01 – Clinical Trials Optional)

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants

Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. Research should be conducted within populations disproportionately affected by opioid use disorder, mental illness or death by suicide. Applications must involve populations disproportionately affected by opioid-related harms and take place within the U.S. and its territories. Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis.

Application Due Date: February 3, 2023

[RFA-CA-22-052](#) (U01 – Clinical Trial Not Allowed)

Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms

Through this FOA, the National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA), and National Center for Complementary and Integrative Health (NCCIH) invite Cooperative Agreement (U01) applications that propose a prospective cohort study to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors, currently receiving treatment, comparing those using with those not using cannabis and cannabinoids. Applicants responding to this FOA should be aware of the companion FOA ([RFA-CA-22-053](#)) for the U24 coordination center. **Application Due Date:** February 18, 2023

[RFA-ES-22-008](#) (R01 Clinical Trial Not Allowed)

[RFA-ES-22-009](#) (R21 Clinical Trial Not Allowed)

Biological Basis for how Environmental Exposures Impact Risk for Psychiatric Disorders

The objective of this FOA is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. The focus of this FOA is to encourage a range of mechanistic approaches, from in vitro systems to whole organism models, to examine the link between environmental chemicals and possible contribution to the pathogenesis of psychiatric abnormalities. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are also welcomed. This FOA will use the NIH Research Project Grant (R01) award mechanism and runs in parallel with the companion FOA, [RFA-ES-22-009](#), which encourages applications under the R21 mechanism. **Application Due Date:** February 22, 2023

[RFA-CA-22-035](#) (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-CA-22-036](#) (K99/R00 – Independent Clinical Trial Required)

[RFA-CA-22-037](#) (K99/R00 – Independent Basic Experimental Studies with Humans Required)

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers

This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply. **Application Due Date:** February 28, 2023

MULTIPLE DUE DATES

[RFA-CA-22-056](#) (R01 Clinical Trial Not Allowed)

[RFA-CA-22-057](#) (R21 Clinical Trial Not Allowed)

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer

Through this FOA, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. **Application Due Dates:** December 15, 2022, December 15, 2023

[RFA-OD-22-028](#) (R01 Clinical Trial Optional)

The Intersection of Sex and Gender Influences on Health and Disease

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#).

Application Due Date: December 19, 2022, November 22, 2023, November 22, 2024

[RFA-CA-22-042](#) (R34 Clinical Trial Optional)

Advancing Adolescent Tobacco Cessation Intervention Research

The purpose of this FOA is to provide support for research to facilitate well planned clinical trials aimed at advancing the science of tobacco cessation among adolescents. Specifically, the FOA invites applications for Planning Grants (R34) to inform the planning, design, and initial development of adolescent tobacco cessation behavioral intervention studies, with an emphasis on the critical developmental risk period ranging from mid- to late adolescence (i.e., approximately 14-20 years old).

Application Due Dates: January 23, 2023, October 16, 2023

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to [RFA-DA-23-054](#), which solicits applications for which pilot data is available.

Application Due Dates: March 20, 2023, November 15, 2023, March 20, 2024

[RFA-CA-22-043](#) (R01 Clinical Trial Required)

Advancing Adolescent Tobacco Cessation Intervention Research

This FOA supports studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid- to late adolescence (approximately 14-20 years old). Projects supported by this FOA must be grounded in the adolescent developmental literature and draw on a well-established theoretical model of behavior change. This FOA runs in parallel with an FOA of similar scientific scope, [RFA-CA-22-042](#) which utilizes the Planning Grant (R34) mechanism. **Application Due Dates:** January 23, 2023, October 16, 2023

[RFA-EB-21-001](#) (R01, Clinical Trial Optional)

Technology Development to Reduce Health Disparities

This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. **Application Due Dates:** January 26, 2023, January 26, 2024

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: February 14, 2023, October 13, 2023, February 13, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nhlbi.nih.gov.

Application Due Dates: June 20, 2023; October 19, 2023, June 20, 2024; and October 21, 2024.

[RFA-CA-22-050](#) (R01 Clinical Trial Optional)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP)

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply.

Application Due Dates: June 6, 2023, February 6, 2024

[RFA-DA-23-013](#) (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV. Research projects should demonstrate that they will have a major impact in improving outcomes related to substance misuse, with a goal of identifying or targeting strategies to prevent, reduce, or eliminate racial and/or ethnic disparities in substance use outcomes. **Application Due Dates:**, November 14, 2023, November 14, 2024

[RFA-DA-23-061](#) (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged. **Application Due Dates:**, November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. **Application Due Dates:**, November 14, 2023, November 14, 2024

[RFA-DA-23-028](#) (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. Applications are strongly encouraged to incorporate a multidimensional and intersectional approach to understanding structural racism, including but not limited to factors such as income inequality, inequities of homeownership, employment, education, incarceration, area deprivation, food insecurity, and neighborhood segregation. In addition to neuroscience/psychology, all applications are expected to incorporate expertise as needed from fields including but not limited to epidemiology, intervention science, community-engaged research, sociology, and/or ethnic studies. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. **Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). **Application Due Dates:**

Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

NCI Outstanding Investigator Award

The Outstanding Investigator Award (R35) is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. Applicants should describe a general research strategy, providing an overview of the broad research questions/scientific questions they plan to address, a general description of possible strategies, and a description of how their past scientific accomplishments will inform this research. Experimental details, extensive preliminary data, and specific aims should not be included unless critical to assessing the feasibility of the new avenues of research.

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-23-034](#) – (R01 Clinical Trial Optional)

NLM Research Grants in Biomedical Informatics and Data Science

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. Applications submitted to this funding opportunity should focus on a well-defined research problem, a rigorous research design, based on preliminary studies, and advance the field of informatics or data science to improve human health. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

Individual Actions for Sustainability

Limit Dryer Usage



Laundry dryers can be energy-inefficient and if your dryer is an older model, it likely will take longer to dry your clothes. Dryers should be used on a limited basis and in its place utilize drying racks all year round and/or hanging clothing out on the clothesline in the warmer months! If you are limited for space for a drying rack or a clothing line outside, wool dryer balls shrink drying times by 30-50%, saving energy and money. They also decrease wrinkles, eliminate static, and are safe for people with sensitive skin. Wool dryer balls work best on natural fibers. What can you do with your dryer balls when they are worn out? If they are 100% wool, they can be composted, but what is even better, add a few drops of essential oil and put them in your closets and drawers!

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras

